Mobile P.E.T. buys seven GE scanners
Five of seven GE PET Advance scanners purchased by Mobile P.E.T. Systems will travel thousands of miles around the U.S. as systems are placed in Northern and Southern California, Ohio, Florida, and Texas.The two remaining positron emission tomography
Five of seven GE PET Advance scanners purchased by Mobile P.E.T. Systems will travel thousands of miles around the U.S. as systems are placed in Northern and Southern California, Ohio, Florida, and Texas.
The two remaining positron emission tomography units will go to states currently in negotiation with the San Diego-based company, said Jill Janek, Mobile P.E.T. Systems marketing official.
The system going to Texas will serve an area where patients cant reach a PET center unless they drive three hours, said John Relic, CEO of the Austin Radiological Association.
GE Medical Systems introduced its first mobile PET camera at last years RSNA show. Mobile P.E.T. has purchased the machines in a lease financing agreement worth $12 million.
In December of last year, GE placed more than 100 Advance PET systems worldwide. The company expects to double that figure this year, said Beth Klein, general manager of GEs global nuclear/PET business (SCAN 12/15/99).
If Mobile P.E.T. is satisfied with the performance of the Advance, it will consider adding more GE scanners to the fleet, Janek said.
Mobile P.E.T. Systems provides shared PET services to hospitals and other healthcare providers on contract. The firm unveiled its first mobile cardiac unit in March (SCAN 2/28/00). The GE scanners do not measure cardiac activity, Janek said.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
